These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 29739463)

  • 61. Influencing health policy through public deliberation: Lessons learned from two decades of Citizens'/community juries.
    Degeling C; Rychetnik L; Street J; Thomas R; Carter SM
    Soc Sci Med; 2017 Apr; 179():166-171. PubMed ID: 28285232
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A Health Economics Approach to US Value Assessment Frameworks-Summary and Recommendations of the ISPOR Special Task Force Report [7].
    Garrison LP; Neumann PJ; Willke RJ; Basu A; Danzon PM; Doshi JA; Drummond MF; Lakdawalla DN; Pauly MV; Phelps CE; Ramsey SD; Towse A; Weinstein MC
    Value Health; 2018 Feb; 21(2):161-165. PubMed ID: 29477394
    [TBL] [Abstract][Full Text] [Related]  

  • 63. How state and federal policies as well as advances in genome science contribute to the high cost of cancer drugs.
    Ramsey SD
    Health Aff (Millwood); 2015 Apr; 34(4):571-5. PubMed ID: 25847638
    [TBL] [Abstract][Full Text] [Related]  

  • 64. American Society of Clinical Oncology guidance statement: the cost of cancer care.
    Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
    J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Drug pricing and value in oncology.
    Danzon PM; Taylor E
    Oncologist; 2010; 15 Suppl 1():24-31. PubMed ID: 20237214
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Solidarity and cost management: Swiss citizens' reasons for priorities regarding health insurance coverage.
    Schindler M; Danis M; Goold SD; Hurst SA
    Health Expect; 2018 Oct; 21(5):858-869. PubMed ID: 29654652
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Stock options, tax credits or employment contracts please! The value of deliberative public disagreement about human tissue donation.
    Walmsley HL
    Soc Sci Med; 2011 Jul; 73(2):209-16. PubMed ID: 21683492
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The development of a value based pricing index for new drugs in metastatic colorectal cancer.
    Dranitsaris G; Truter I; Lubbe MS
    Eur J Cancer; 2011 Jun; 47(9):1299-304. PubMed ID: 21493060
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The role of economic evidence in Canadian oncology reimbursement decision-making: to lambda and beyond.
    Rocchi A; Menon D; Verma S; Miller E
    Value Health; 2008; 11(4):771-83. PubMed ID: 18179658
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Improving hospital quality through payment reforms: A policy impact analysis in British Columbia.
    Hellsten E; Liu G; Yue E; Gao G; Sutherland JM
    Healthc Manage Forum; 2016 Jan; 29(1):33-8. PubMed ID: 26656392
    [TBL] [Abstract][Full Text] [Related]  

  • 71. An Australian approach to the policy translation of deliberated citizen perspectives on biobanking.
    Molster C; Maxwell S; Youngs L; Potts A; Kyne G; Hope F; Dawkins H; O'Leary P
    Public Health Genomics; 2012; 15(2):82-91. PubMed ID: 22179074
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Expensive cancer drugs and just health care.
    Ehni HJ
    Best Pract Res Clin Gastroenterol; 2014 Apr; 28(2):327-37. PubMed ID: 24810193
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Public Deliberation Process on Patient Perspectives on Health Information Sharing: Evaluative Descriptive Study.
    Raj M; Ryan K; Nong P; Calhoun K; Trinidad MG; De Vries R; Creary M; Spector-Bagdady K; Kardia SLR; Platt J
    JMIR Cancer; 2022 Sep; 8(3):e37793. PubMed ID: 36112409
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Public Engagement through Inclusive Deliberation: The Human Genome International Commission and Citizens' Juries.
    Scheinerman N
    Am J Bioeth; 2023 Dec; 23(12):66-76. PubMed ID: 36476040
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Perceptions of Oncologists, Healthcare Policy Makers, Patients and the General Population on the Value of Pharmaceutical Treatments in Oncology.
    Sacristán JA; Lizan L; Comellas M; Garrido P; Avendaño C; Cruz-Hernández JJ; Espinosa J; Dilla T
    Adv Ther; 2016 Nov; 33(11):2059-2068. PubMed ID: 27718158
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Deliberation on Childhood Vaccination in Canada: Public Input on Ethical Trade-Offs in Vaccination Policy.
    O'Doherty KC; Crann S; Bucci LM; Burgess MM; Chauhan A; Goldenberg MJ; McMurtry CM; White J; Willison DJ
    AJOB Empir Bioeth; 2021; 12(4):253-265. PubMed ID: 34328070
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Difficult decisions in times of constraint: criteria based resource allocation in the Vancouver Coastal Health Authority.
    Mitton C; Dionne F; Damji R; Campbell D; Bryan S
    BMC Health Serv Res; 2011 Jul; 11():169. PubMed ID: 21756357
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Sharing linked data sets for research: results from a deliberative public engagement event in British Columbia, Canada.
    Teng J; Bentley C; Burgess MM; O'Doherty KC; McGrail KM
    Int J Popul Data Sci; 2019 May; 4(1):1103. PubMed ID: 34095532
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Public values and plurality in health priority setting: What to do when people disagree and why we should care about reasons as well as choices.
    Baker R; Mason H; McHugh N; Donaldson C
    Soc Sci Med; 2021 May; 277():113892. PubMed ID: 33882440
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Conditional approval of cancer drugs in Canada: accountability and impact on public funding.
    Andersen SK; Penner N; Chambers A; Trudeau ME; Chan KKW; Cheung MC
    Curr Oncol; 2019 Feb; 26(1):e100-e105. PubMed ID: 30853815
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.